The Effect of a Pre-meal Snack and/or Exercise on Post-prandial Glycemic Excursions in Adults With Cystic Fibrosis (SNACK_CF)

The investigators aim to test the feasibility and effectiveness of a pre-meal snack to reduce the postprandial glycemia (PPG) excursion after a breakfast consumption in adult patients with cystic fibrosis (CF). The investigators also want to investigate the impact of a postprandial exercise to reduce the PPG excursion. An improvement in PPG excursions can improve the condition of CF patients primarily by delaying the onset of cystic fibrosis related diabetes (CFRD) and / or by reducing the risk of lung function loss.

Study Overview

Status

Completed

Conditions

Detailed Description

The investigators are proposing a randomized pilot study to explore the impact of a soy beverage of carbohydrates and protein early in the morning, to stimulate and initiate secretion of Insulin to reduce PPG excursions of the following a lunch in adult patients with CF. Investigators will also study the impact of a post meal exercise on the PPG excursion. Fourteen participants will be included and will each perform a 4-hour intervention in cross over design according to those 4 following experimental conditions:

  1. Consumption of 200ml of water (flavored) + breakfast of 90g of carbohydrates (CHO) for men and 80g for women; Sedentary activities throughout the study [condition control]
  2. Consumption of 200ml of soy beverage + 90g of carbohydrate (CHO) breakfast for men and 80g for women; Sedentary activities throughout the study [snack effect on PPG excursion]
  3. Consumption of 200ml of water (flavored) + breakfast of 90g of carbohydrates (CHO) for men and 80g for women + physical activity practice (3min walk at 60% VO2max every 30 minutes, x5); [exercise effect on the PPG excursion]
  4. Consumption of 200ml of soy beverage + breakfast of 90g of carbohydrate (CHO) breakfast for men and 80g for women + physical activity practice (3min walk at 60% VO2max every 30 minutes, x5). [Combined snack and exercise effect on the PPG excursion] Main result: plasma glucose area under the curve. The underlying mechanisms, insulin, incretin hormones (GLP-1 and GIP), acceptability and side effects (mealtime hyperglycaemia) should also be measured. At the end of this pilot project, the investigators will have established a pre-meal snack and/ or postprandial exercise have a positive impact on PPG.

Study Type

Interventional

Enrollment (Actual)

14

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Quebec
      • Montreal, Quebec, Canada, H2W 1R7
        • Institut de recherches cliniques de Montréal (IRCM)

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Diagnosis of cystic fibrosis,
  • Be over 18 years old.

Exclusion Criteria:

  • Pharmacological treatment for cystic fibrosis related diabetes.
  • Signs of secondary infection: the test will be practiced at least 1 month after the end of infection treatment
  • People with severe gastrointestinal illness (Crohn's disease, celiac disease and a recent history (<1 year) of bowel obstruction).
  • Allergy to one of the ingredients of the menu (example: celiac disease)
  • According to the judgment of the investigator, medications or conditions that could interfere with glucose metabolism (eg: oral steroids)
  • Pregnancy in progress
  • Corrector or potentiator prescribed whose dose is not stable the last 2 months.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: [Placebo + Sedentary]
1) Consumption of 200ml of water (flavored) + breakfast of 90g of carbohydrates (CHO) for men and 80g for women; Sedentary activities throughout the study
Experimental: [Snack effect + Sedentary]
2) Consumption of 200ml of soy beverage + 90g of carbohydrate (CHO) breakfast for men and 80g for women; Sedentary activities throughout the study
Consumption of a 200ml of soy beverage (100Kcal, 11g CHO, 6g proteins, 4g fat)
Experimental: [Placebo + Exercise]
3) Consumption of 200ml of water (flavored) + breakfast of 90g of carbohydrates (CHO) for men and 80g for women + physical activity practice (3min walk at 60% VO2max every 30 minutes, x5);
3min walk at 60% VO2max every 30 minutes,(x5)
Experimental: [Snack + Exercise]
4) Consumption of 200ml of soy beverage + breakfast of 90g of carbohydrate (CHO) breakfast for men and 80g for women + physical activity practice (3min walk at 60% VO2max every 30 minutes, x5).
Consumption of a 200ml of soy beverage (100Kcal, 11g CHO, 6g proteins, 4g fat)
3min walk at 60% VO2max every 30 minutes,(x5)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Total area under the curve for plasma glucose
Time Frame: Overall study period (4 hours)
Overall study period (4 hours)

Secondary Outcome Measures

Outcome Measure
Time Frame
Area under the curve for plasma glucose
Time Frame: From start of study to breakfast time (1 hour)
From start of study to breakfast time (1 hour)
Area under the curve for plasma glucose
Time Frame: From time of breakfast to the end of the study (3 hours)
From time of breakfast to the end of the study (3 hours)
Total area under the curve for insulin
Time Frame: Overall study period (4 hours)
Overall study period (4 hours)
Area under the curve for insulin
Time Frame: From start of study to breakfast time (1 hour)
From start of study to breakfast time (1 hour)
Area under the curve for insulin
Time Frame: From breakfast time to the end of the study (3 hours)
From breakfast time to the end of the study (3 hours)
Mean plasma glucose
Time Frame: Overall study period (4 hours)
Overall study period (4 hours)
Mean insulin
Time Frame: Overall study period (4 hours)
Overall study period (4 hours)
Percentage of time with plasma glucose concentration above 8.0 mmol/L
Time Frame: Overall study period (4 hours)
Overall study period (4 hours)
Percentage of time with plasma glucose concentration above 10.0 mmol/L
Time Frame: Overall study period (4 hours)
Overall study period (4 hours)
Percentage of time with plasma glucose concentration above 11.0 mmol/L
Time Frame: Overall study period (4 hours)
Overall study period (4 hours)
Percentage of time with plasma glucose concentration below 4.0 mmol/L
Time Frame: Overall study period (4 hours)
Overall study period (4 hours)
Post-breakfast peak plasma glucose
Time Frame: 1 hour after breakfast
1 hour after breakfast

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Rémi Rabasa-Lhoret, MD, PhD, IRCM

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 1, 2019

Primary Completion (Actual)

May 26, 2022

Study Completion (Actual)

December 31, 2022

Study Registration Dates

First Submitted

June 20, 2018

First Submitted That Met QC Criteria

October 15, 2018

First Posted (Actual)

October 18, 2018

Study Record Updates

Last Update Posted (Actual)

April 25, 2023

Last Update Submitted That Met QC Criteria

April 24, 2023

Last Verified

April 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cystic Fibrosis

Clinical Trials on Snack beverage

Subscribe